Drug Trial Radar · NCT05173792
Study of AK119 in Subjects With Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Apr 25, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
16
Actual
Start
Dec 22, 2021
Primary completion
May 22, 2023
Study completion May 22, 2023
Sponsor
- Lead sponsor
- AkesoIndustry
- Sponsor type
- Industry
- First posted
- Dec 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is Phase 1, Multicenter, Open-Label, Dose-Escalation and Dose-Exploration Study to Evaluate the Safety, Pharmacokinetics, and Anti-tumor Activity of AK119 (Anti-CD73) in Subjects with Advanced or Metastatic Solid Tumors.
Conditions
- Solid Tumor
Interventions
AK119Drug
Subjects will receive AK119 intravenously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs)Time frame: From the time of informed consent signed through 90 days after the last dose of study drug
- Number of participants with a Dose Limiting Toxicity (DLT)Time frame: During the first 4 weeks in dose-escalation phase, during the first 3 weeks in dose-exploration phase
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Fudan University Zhongshan Hospital
Shanghai, China
Tianjin Medical University Cancer Institute & Hospital
Tianjin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.